"Sense of urgency" is certainly not in Amarin's vocabulary. From top line Reduce it to submittal to FDA to whatever they're planning to do in Europe or the ROW, it's like island time or maybe Calle Ocho. And there's no sign of diversification - with the $600 million they have, you'd think they might have explored some opportunities. On a side note, the one poster on this board that admonishes other posters on a daily basis about investing too heavily in Amarin and the need to diversify one's portfolio has invested in this one trick pony - how ironic.
News 
Market Data 
Discover 
